A Phase 1/2 interventional study of Givinostat in Duchenne Muscular Dystrophy (DMD), sponsored by Italfarmaco. Completed at 4 sites in Italy. Open to male participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Italfarmaco · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Muscular Dystrophy, Duchenne with a site in Italy — 19 open to participants now, 26 under way, 7 of them phase 3. Muscular Dystrophy, Duchenne · Italy.
Among the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, this one is the 50th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2013, is one of 11 in phase 1/2, and was the 17th registered.
481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →19 of the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Italy, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Istituto Giannina Gaslini · Sites in Italy
Ages 18+ · Men only
Entrada Therapeutics, Inc. · Sites in Italy, Belgium, Netherlands and 2 more countries
Ages 4–20 · Men only
Universita di Verona · Sites in Italy
Ages 16–65
Entrada Therapeutics, Inc. · Sites in Italy, Belgium, Spain and 1 more country
Ages 4–20 · Men only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 11 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 34 · Phase 3 27 · Phase 4 1
First in 2005; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 26 across 332 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 73 across the 67 interventional studies, 225 across the 14 observational. Of the 51 that completed or were terminated, 29 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 82 have an industry lead sponsor. The 10 most frequent:
Italfarmaco is the lead sponsor of 35 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Italfarmaco has 8 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
6 of the studies in Muscular Dystrophy, Duchenne with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT06450639Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | 2026-11-18 |
| NCT06280209BioMarin PharmaceuticalA Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | 2027-04-14 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
| NCT07101185IRCCS Eugenio MedeaTransition to Adulthood in People With Muscular Dystrophy | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of Parts 1 and 2 of the study were to establish the histologic effects of givinostat administered chronically at the selected daily dose.
The secondary objectives of Parts 1 and 2 of the study were as follows:
The primary objective of the Extension of the study was to evaluate the safety and tolerability of long-term administration of givinostat administered chronically at the selected daily dose in children with DMD.
The secondary objectives of the Extensions were:
This is a 2-part, phase II study to assess the effects of Givinostat on muscle histologic parameters and on clinical parameters in ambulant children with DMD.
The safety, tolerability, and pharmacokinetics of Givinostat will also be assessed.
Approximately 20 children were to be enrolled in the study as follows: the first 4 children were to be treated at a low dose level of givinostat (25 mg twice daily [BID] in children who weighed 20 kg to 49 kg and 37.5 mg BID in children who weighed ≥ 50 kg).
If none of the stopping criteria were met after 2 weeks of treatment at the low dose, the review team was to determine the escalated dose level (ie, intermediate dose level) to be used for the treatment of an additional 8 children who were to be treated at the intermediate dose. The 4 children previously treated at the low dose level were also switched to the intermediate dose level.
If none of the stopping criteria were met after 2 weeks of treatment at the intermediate dose, the review team was to determine the subsequent escalated dose level to be used for the treatment of an additional 8 children who were to be treated at the high dose. All children treated at the intermediate dose level were to be switched to the high dose level.
Once all 20 children enrolled during Part 1 of the study had been treated for at least 2 weeks, the review team was to determine the recommended dose (RD) to be used in Part 2 based on the safety and tolerability profile observed and on the pharmacokinetic (PK) analyses. All the children enrolled were switched to the RD level (37.5 mg BID), which was administered for the subsequent 12 months of the study (Part 2).
At the end of Part 2 of the study, parents were asked to consent and patients to assent to continuing their participation in the Extension to receive the study treatment at least until the final analysis was performed (Part 3-Extensions; after 52 months of treatment). The patients received givinostat at the same ongoing dose, during the last visit planned at 12 months, and were treated for additional 40 months (Extensions 1, 2, and 3 up to month 52).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Givinostat will be administered as 2 oral doses daily while the child is in fed state.
Drug: Givinostat
Givinostat, oral suspension 10 mg/mL or oral capsules 50 mg, administered orally under fed conditions at the dose of 25 mg BID, 37.5 mg BID, and 50 mg BID during Part 1 for two weeks, and 25 mg BID and 37.5 mg BID during Part 2 for 12 months. Givinostat, oral suspension 10 mg/mL, administered orally under fed conditions at the dose of 25 mg BID or 37.5 mg BID during Extension 1, and modified as per patient's weight during Extensions 2 and 3 (up to 52 months).
Also known as: ITF2357
Change From Baseline to Part 2 in the Value of Muscle Fiber Area (MFA) % Comparing the Histology Biopsies Before and After 12 Months of Treatment With Givinostat.
The primary endpoint was the change in histology comparing the brachial biceps biopsies before and after ≥12 months of treatment with Givinostat. Muscle biopsies: A first brachial biceps biopsy (baseline) was taken prior to the first dose of study drug. A second brachial biceps biopsy was taken at Visit 10 (12 months) from the opposite arm. The muscle biopsy samples from the biceps muscle were collected by open biopsy. The minimum amount of muscle tissue required was a piece of muscle of at least 0.5 × 0.5 × 0.5 cm.
Time frame: After12 months of treatment
Change From Baseline to End of Study in Cross Sectional Area (CSA)
This histological parameter was evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat.
Time frame: At 12 months
Change From Baseline to End of Study in Fibrosis, Necrosis, Fatty Replacement
These histological parameters were evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat.
Time frame: After 12 months
Change From Baseline to End of Study in Number of Hypercontracted Fibers
This histological parameter was evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat. The number of fibers is calculated per microscopic field (20x).
Time frame: At 12 months
Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the 6-Minute Walk Test
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. The longer the walked distance the better the outcome.
Time frame: At 12 months
Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the North Star Ambulatory Assessment (NSAA)
The NSAA, which is composed by 17 items, was graded, for each item, using the standard scorecard with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. The subscales scores are summed up to compute a total score, ranging from 0 to 34. The higher the total score, the better the outcome. The mean Change From Baseline to EoS in NSAA total score is reported hereunder.
Time frame: At 12 months
Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the Performance of Upper Limb (PUL)
The PUL (version 1.2) was used to assess the change in motor performance of the upper limb over time in patients with Becker and Duchenne muscular dystrophy, from when they are still ambulant, until they loose all arm function when non-ambulant. The revised version of the PUL included 22 items. These include one entry item to define the starting functional level, and 21 items subdivided into: * shoulder level (Question B to E; minimum score 0 and maximum score 16) * elbow level (Question F to N; minimum score 0 and maximum score 34) * distal level dimension (Question O to V; minimum score 0 and maximum score 24) The total score is calculated by the sum of all the scores of the three subscales (total score range: 0-74) (scores from Question A "entry item" did not contribute). For all items, the higher the score, the better the outcome.
Time frame: At 12 months
Change From Baseline in Muscular Function After After 24 (Extension 1), 36 (Extension 2), and 52 Months (Extension 3) of Treatment With Givinostat at the Selected Daily Dose Based on the 6-Minute Walk Test
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. The longer the walked distance the better the outcome.
Time frame: At 24, 36, and 52 months
Change From Baseline in Muscular Function After 24 (Extension 1), 36 (Extension 2), and 52 Months (Extension 3) of Treatment With Givinostat at the Selected Daily Dose Based on the North Star Ambulatory Assessment (NSAA)
The NSAA, which is composed by 17 items, was graded, for each item, using the standard scorecard with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. The subscales scores are summed up to compute a total score, ranging from 0 to 34. The higher the total score, the better the outcome. The mean Change From Baseline to EoS in NSAA total score is reported hereunder.
Time frame: At 24, 36, and 52 months
Change From Baseline in Muscular Function After 24 (Extension 1), 36 (Extension 2), and 52 Months (Extension 3) of Treatment With Givinostat at the Selected Daily Dose Based on the Performance of Upper Limb (PUL)
The PUL (version 1.2) was used to assess the change in motor performance of the upper limb over time in patients with Becker and Duchenne muscular dystrophy, from when they are still ambulant, until they loose all arm function when non-ambulant. The revised version of the PUL included 22 items taking. These include one entry item to define the starting functional level, and 21 items subdivided into: * shoulder level (Question B to E; minimum score 0 and maximum score 16) * elbow level (Question F to N; minimum score 0 and maximum score 34) * distal level dimension (Question O to V; minimum score 0 and maximum score 24) The total score is calculated by the sum of all the scores of the three subscales (total score range: 0-74) (scores from Question A "entry item" did not contribute). For all items, the higher the score, the better the outcome.
Time frame: At 24, 36, and 52 months
Number of Children Experiencing Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Type and Severity of TEAEs
Summary of Treatment-emergent Adverse Events (TEAE) Reporting from Baseline to the End of Extension 3 (Month 52). In the analysis were included: Any TEAE, Any treatment-related TEAE, Any mild or moderate or severe TEAE, Any life-threatening or disabling TEAE, Any TEAE resulting in death, any serious adverse event, and Any TEAE resulting in study discontinuation.
Time frame: Part 1, Part 2, and Extensions 1, 2, and 3
| Milestone | Givinostat |
|---|---|
| Started | 20 |
| Patients receiving drug in part 1 | 19 |
| Completed | 18 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Not receiving treatment in part 1 | 1 |
| Milestone | Givinostat |
|---|---|
| Started | 19 |
| Completed | 19 |
| Not completed | 0 |
| Milestone | Givinostat |
|---|---|
| Started | 19 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Givinostat |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | Givinostat |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
The primary endpoint was the change in histology comparing the brachial biceps biopsies before and after ≥12 months of treatment with Givinostat. Muscle biopsies: A first brachial biceps biopsy (baseline) was taken prior to the first dose of study drug. A second brachial biceps biopsy was taken at Visit 10 (12 months) from the opposite arm. The muscle biopsy samples from the biceps muscle were collected by open biopsy. The minimum amount of muscle tissue required was a piece of muscle of at least 0.5 × 0.5 × 0.5 cm.
| percentage change | Overall |
|---|---|
| Change From Baseline to Part 2 in the Value of Muscle Fiber Area (MFA) % Comparing the Histology Biopsies Before and After 12 Months of Treatment With Givinostat. | 12.76 (6.17 to 21.23) |
This histological parameter was evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat.
| μm2 | Overall |
|---|---|
| Change From Baseline to End of Study in Cross Sectional Area (CSA) | 865.269 ± 555.3543 |
These histological parameters were evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat.
| percentage of total area | Baseline |
|---|---|
| Total fibrosis | -12.640 ± 4.6493 |
| Perimysial fibrosis | -7.585 ± 6.4779 |
| Endomysial fibrosis | -5.056 ± 6.2531 |
| Fatty replacement | -0.302 ± 0.2756 |
| Necrosis | -0.964 ± 0.6260 |
This histological parameter was evaluated on the brachial biceps biopsies taken prior to the first dose of study drug and after 12 months of treatment with givinostat. The number of fibers is calculated per microscopic field (20x).
| number of fibers | Overall |
|---|---|
| Change From Baseline to End of Study in Number of Hypercontracted Fibers | -1.204 ± 0.6621 |
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. The longer the walked distance the better the outcome.
| meters | Overall |
|---|---|
| Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the 6-Minute Walk Test | -24.6 ± 36.11 |
The NSAA, which is composed by 17 items, was graded, for each item, using the standard scorecard with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. The subscales scores are summed up to compute a total score, ranging from 0 to 34. The higher the total score, the better the outcome. The mean Change From Baseline to EoS in NSAA total score is reported hereunder.
| score on a scale | Overall |
|---|---|
| Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the North Star Ambulatory Assessment (NSAA) | -2.8 ± 3.15 |
The PUL (version 1.2) was used to assess the change in motor performance of the upper limb over time in patients with Becker and Duchenne muscular dystrophy, from when they are still ambulant, until they loose all arm function when non-ambulant. The revised version of the PUL included 22 items. These include one entry item to define the starting functional level, and 21 items subdivided into: * shoulder level (Question B to E; minimum score 0 and maximum score 16) * elbow level (Question F to N; minimum score 0 and maximum score 34) * distal level dimension (Question O to V; minimum score 0 and maximum score 24) The total score is calculated by the sum of all the scores of the three subscales (total score range: 0-74) (scores from Question A "entry item" did not contribute). For all items, the higher the score, the better the outcome.
| score on a scale | Overall |
|---|---|
| Change From Baseline in Muscular Function After 12 Months of Treatment With Givinostat at the Selected Daily Dose Based on the Performance of Upper Limb (PUL) | -0.2 ± 2.69 |
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. The longer the walked distance the better the outcome.
| meters | Overall |
|---|---|
| Extension 1 | -80.0 ± 110.69 |
| Extension 2 | -127.0 ± 110.40 |
| Extension 3 | -287.8 ± 159.47 |
The NSAA, which is composed by 17 items, was graded, for each item, using the standard scorecard with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. The subscales scores are summed up to compute a total score, ranging from 0 to 34. The higher the total score, the better the outcome. The mean Change From Baseline to EoS in NSAA total score is reported hereunder.
| score on a scale | Overall |
|---|---|
| Extension 1 | -5.2 ± 5.06 |
| Extension 2 | -7.4 ± 5.90 |
| Extension 3 | -15.2 ± 7.83 |
The PUL (version 1.2) was used to assess the change in motor performance of the upper limb over time in patients with Becker and Duchenne muscular dystrophy, from when they are still ambulant, until they loose all arm function when non-ambulant. The revised version of the PUL included 22 items taking. These include one entry item to define the starting functional level, and 21 items subdivided into: * shoulder level (Question B to E; minimum score 0 and maximum score 16) * elbow level (Question F to N; minimum score 0 and maximum score 34) * distal level dimension (Question O to V; minimum score 0 and maximum score 24) The total score is calculated by the sum of all the scores of the three subscales (total score range: 0-74) (scores from Question A "entry item" did not contribute). For all items, the higher the score, the better the outcome.
| score on a scale | Overall |
|---|---|
| Extension 1 | -0.2 ± 2.71 |
| Extension 2 | -0.2 ± 2.75 |
| Extension 3 | -4.4 ± 6.09 |
Summary of Treatment-emergent Adverse Events (TEAE) Reporting from Baseline to the End of Extension 3 (Month 52). In the analysis were included: Any TEAE, Any treatment-related TEAE, Any mild or moderate or severe TEAE, Any life-threatening or disabling TEAE, Any TEAE resulting in death, any serious adverse event, and Any TEAE resulting in study discontinuation.
| participants | Overall |
|---|---|
| TEAEs | 20 |
| Any treatment-related TEAE | 20 |
| Any mild TEAE | 20 |
| Any moderate TEAE | 16 |
| Any severe TEAE | 9 |
| Any life-threatening or disabling TEAE | 1 |
| Ant TEAE resulting in death | 0 |
| Any SAE | 8 |
| Any TEAE resulting in study discontinuation | 1 |
Collected over Adverse events (AE) were assessed throughout the study: in Part 1 (screen, weeks 0, 1, 2, 3, 4, 5); Part 2 (months 0, 1, 2, 3, 4.5, 6, 7.5, 9, 10.5,12); Extension 1 (months 14,16,18, 20, 22, 24, FU); Extension 2 (months 26,28, 30,32, 34, 36, FU); Extension 3 (months 40, 44, 48, 52, FU). Extensions 1, 2 and 3 together represent Part 3 of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 - 25 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Part 1 - 50 mg | 0/12 (0%) | 1/12 (8.3%) | 12/12 (100%) |
| Part 1 - 37.5 mg | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part 2 - 37.5 mg | 0/19 (0%) | 1/19 (5.3%) | 19/19 (100%) |
| Part 2 - 25 mg | 0/12 (0%) | 1/12 (8.3%) | 12/12 (100%) |
| Overall (Part 1 + Part 2 + Extensions 1, 2, 3 ) | 0/20 (0%) | 8/20 (40%) | 20/20 (100%) |
| Event | Part 1 - 25 mg | Part 1 - 50 mg | Part 1 - 37.5 mg | Part 2 - 37.5 mg | Part 2 - 25 mg | Overall (Part 1 + Part 2 + Extensions 1, 2, 3 ) |
|---|---|---|---|---|---|---|
| Femural fractureInjury, poisoning and procedural complications | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 2/20 |
| Platelet count decreasedInvestigations | 0/4 | 1/12 | 0/7 | 0/19 | 0/12 | 2/20 |
| Lower limb fractureGeneral disorders | 0/4 | 0/12 | 0/7 | 0/19 | 1/12 | 1/20 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/4 | 0/12 | 0/7 | 1/19 | 0/12 | 1/20 |
| Cushing's syndromeEndocrine disorders | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 1/20 |
| CataractsEye disorders | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 1/20 |
| Chest painGeneral disorders | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 1/20 |
| HaematuriaRenal and urinary disorders | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 1/20 |
| HypertensionVascular disorders | 0/4 | 0/12 | 0/7 | 0/19 | 0/12 | 1/20 |
| Event | Part 1 - 25 mg | Part 1 - 50 mg | Part 1 - 37.5 mg | Part 2 - 37.5 mg | Part 2 - 25 mg | Overall (Part 1 + Part 2 + Extensions 1, 2, 3 ) |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/4 | 5/12 | 3/7 | 9/19 | 6/12 | 15/20 |
| Platelet count decreasedInvestigations | 0/4 | 1/12 | 0/7 | 13/19 | 5/12 | 13/20 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/12 | 2/7 | 5/19 | 0/12 | 11/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/4 | 0/12 | 0/7 | 2/19 | 0/12 | 10/20 |
| PyrexiaGeneral disorders | 0/4 | 1/12 | 1/7 | 3/19 | 3/12 | 9/20 |
| InfluenzaInfections and infestations | 0/4 | 0/12 | 1/7 | 2/19 | 1/12 | 9/20 |
| VomitingGastrointestinal disorders | 0/4 | 0/12 | 1/7 | 2/19 | 3/12 | 8/20 |
| FallInjury, poisoning and procedural complications | 0/4 | 0/12 | 1/7 | 1/19 | 2/12 | 8/20 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 0/12 | 1/7 | 4/19 | 2/12 | 7/20 |
| White blood cell count decreasedInvestigations | 0/4 | 4/12 | 0/7 | 1/19 | 0/12 | 4/20 |
The ITT population included all children who were enrolled in the Part 1 portion or entered the Part 2 portion of the study. Patients were analyzed according to the dose level to which they were allocated. Twenty patients were included in the ITT population.
| Age, Categorical(Participants) | ITF2357 25 mg BID | ITF2357 50 mg BID | ITF2357 37.5 mg BID | Total |
|---|---|---|---|---|
| <=18 years | 4 | 8 | 8 | 20 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | ITF2357 25 mg BID | ITF2357 50 mg BID | ITF2357 37.5 mg BID | Total |
|---|---|---|---|---|
| Mean | 7.8 ± 0.96 | 8.8 ± 1.16 | 7.9 ± 1.13 | 8.2 ± 1.15 |
| Sex: Female, Male(Participants) | ITF2357 25 mg BID | ITF2357 50 mg BID | ITF2357 37.5 mg BID | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 4 | 8 | 8 | 20 |
| Region of Enrollment(participants) | ITF2357 25 mg BID | ITF2357 50 mg BID | ITF2357 37.5 mg BID | Total |
|---|---|---|---|---|
| Italy | 4 | 8 | 8 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Apr 2013, a primary completion of Dec 2014 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2020, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Givinostat
Muscular Dystrophy, Duchenne →